1. Scrip
  2. >>Business
  3. >>Deals

Eisai Boards Fast Boat To China In HER2-Targeting ADC Deal With Bliss

 
• By Alaric DeArment

The Japanese drug maker is the second in the space of a month to partner up with a Chinese biotech firm for a HER2-targeting antibody-drug conjugate, as ADCs gain more interest from large pharma firms.

Eisai announced a deal with BlissBio for the Chinese company's HER2-directed ADC • Source: Shutterstock

With the success of AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Enhertu (fam-trastuzumab daruxtecan-nxki), a number of drug makers are hoping to get in on the HER2 game as well, in some cases looking to companies in China developing HER2-targeting antibody-drug conjugates (ADC). Japanese drug maker Eisai Co., Ltd. is the latest firm to take that route with a development partnership centered on Bliss Biopharmaceutical Co. Ltd.’s Phase I/II ADC candidate.

Hangzhou, China-based BlissBio said 7 May that it had signed a clinical trial collaboration agreement with Eisai with an option...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

More from Business

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.